VeriTeQ Acquisition Corporation acquires implantable, FDA-Cleared VeriChip technologyJanuary 17, 2012 | Industry News Release
VeriTeQ Acquisition Corporation (“VeriTeQ” or “Company”), a marketer of implantable, radio frequency identification (“RFID”) technologies for patient identification and sensor applications, announced today it has acquired the VeriChip implantable microchip and related technologies, and Health Link personal health record from PositiveID Corporation. VeriTeQ is majority owned and led by Scott R. Silverman, former Chairman and CEO of PositiveID and VeriChip Corporation. PositiveID has retained an ownership interest in VeriTeQ.
VeriTeQ will focus on three main areas: patient identification and personal health record (PHR) access through the VeriChip implantable microchip and Health Link web-based PHR; implantable sensor applications; and identification of medical devices within the body. VeriTeQ will also focus on identification and sensor applications for animals.
VeriChip is the first and only FDA-cleared RFID implantable microchip for humans and patient identification. In addition to acquiring VeriChip, the Company has also licensed a patent for an “Embedded Bio-Sensor System” to be used in conjunction with an implantable microchip, which will enable it to develop sensor applications for use within the body.
VeriTeQ’s acquisition also includes the rights to a Development and Supply Agreement with Medical Components, Inc. (“Medcomp”), a leading manufacturer of vascular access catheters. Under the terms of the agreement, Medcomp will embed the VeriChip microchip in its vascular ports to facilitate identification of the port in a patient and proper medication dispensing. The initial term of the agreement is five years, totaling more than $3.0 million over the life of the agreement, assuming Medcomp’s receipt of FDA approval of the vascular port containing the microchip.
Silverman stated, “I have always been a believer in the broad range of potential applications stemming from implantable RFID technology. With the growth of mobile health platforms, implantable RFID microchips can provide an important link for patients, their medical records, vital signs and other important data.”
VeriTeQ develops and markets innovative, implantable RFID technologies for humans and animals including sensor applications. VeriChip is the first human-implantable passive RFID microchip cleared for medical use by the U.S. Food and Drug Administration. For more information on VeriTeQ, please call 1-800-805-8011.